[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-hospitalization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-hospitalization":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644611","non-invasive-hemodynamic-monitoring-in-hospitalized-heart-failure-100644611",false,"NCT07671742","Non-Invasive Hemodynamic Monitoring in Hospitalized Heart Failure","Hemodynamic Observational Study in Patients With Heart Failure Using a Non-Invasive Multi-Modal Sensing Device (HOSP-HF)","Inclusion Criteria:\n\n* Age ≥18 years\n* Hospitalization for primary heart failure, defined as new or worsening heart failure symptoms with objective evidence of congestion requiring initiation or intensification of heart failure-specific therapy\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Any discretionary exclusion where the inclusion of the subject is deemed to pose potential risks to the subject's well-being or is likely to comprise the compliant performance of the study.\n* Pregnancy or lactation (as confirmed by self-report or medical documentation)\n* Presence of a skin rash or open wound in the area where the Acorai Device model 1.0 will be applied\n* Any other condition that, in the opinion of the investigator, would preclude the subject from participating in the study or may affect the integrity of the data","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Heart failure hospitalization is associated with a high risk of early readmission and mortality. There is an unmet clinical need for low-burden, non-invasive methods to better understand congestion and hemodynamic status during hospitalization.\n\nThis observational study evaluates the association between non-invasive measurements obtained with the Acorai Device 1.0 and clinical data collected during hospitalization and up to 90 days after discharge in patients admitted with heart failure. The device performs short, non-invasive recordings that collect physiological signals from the thoracic region without influencing clinical care.\n\nParticipants will undergo daily recordings during hospitalization. Clinical information and outcomes, including heart failure hospitalization and all-cause mortality within 90 days after discharge, will be collected from medical records. The study aims to explore relationships between non-invasive sensor measurements and clinical outcomes in hospitalized heart failure patients.",[24,25,26],"Heart Failure","Heart Failure Hospitalization","Heart Failure (HF)","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":31},"2026-04-01",{"date":35,"type":20},"2027-04-01",{"name":37,"class":38},"Acorai AB","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100630156","reds-guided-decongestion-strategy-in-patients-hospitalized-for-heart-failure-100630156","NCT07484009","ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure","ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure: the ReDS-SAFE HF II Trial","ReDS-SAFE HF 2","Inclusion Criteria:\n\n1. Hospitalized due to heart failure as the main reason, including the presence of symptoms and signs of congestion, regardless of the left ventricular ejection fraction (LVEF).\n2. NT-proBNP greater than 1000 pg\u002FL or BNP greater than 300 pg\u002FL upon admission.\n\nExclusion Criteria:\n\n1. Height less than 150 cm or greater than 190 cm or body mass index (BMI) less than 22 or greater than 39, conditions where the use of ReDS is not approved.\n2. Patients requiring inotropes (levosimendan is allowed) or vasopressors upon admission, with mechanical support, or heart transplant recipients.\n3. Any malformation or variant affecting the right lung anatomy (e.g., a pacemaker).\n4. Patients with any heart disease requiring a planned surgical intervention (CABG, valve disease, or other) or percutaneous (TAVR, STE-ACS, mitral or tricuspid valve repair, CRT) during the clinical trial.\n5. Chronic kidney disease with a GFR \\\u003C20 or on hemodialysis.\n6. Life expectancy less than 12 months due to non-cardiological origin.\n7. Participation in another clinical trial with intervention.",{"count":49,"type":20},1014,"INTERVENTIONAL",[52],"NA","This clinical trial aims to determine whether a ReDS-guided treatment strategy is superior to the current standard of care for adults hospitalized with heart failure. Additionally, the study will evaluate the safety and cost-effectiveness of this approach.\n\nThe study seeks to answer the following key questions:\n\n1. Does the ReDS-guided strategy reduce the risk of cardiovascular events during the first month following hospital discharge?\n2. What is the safety profile of this treatment strategy?\n\nResearchers will compare the ReDS-based strategy against the current standard of care. All participants will:\n\n* Undergo daily assessments using the ReDS device throughout their hospitalization.\n* Attend two follow-up visits post-discharge, scheduled at 2 weeks and 30 days.",[55,56,25],"Acute Heart Failure (AHF)","Heart Failure (for Example, Fluid Overload)",[58,59,60,61,62],"Heart failure","Congestion","ReDS","Fluid Overload","Randomized Clinical Trial","2026-03-16",{"date":65,"type":31},"2026-03-19",{"date":67,"type":31},"2026-01-29",{"date":69,"type":20},"2027-08-31",{"name":71,"class":72},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","OTHER",25]